Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that CEO Dr. Zheng Wei will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 4:20 PM ET. The chat will be accessible via a webcast on the company's Investor Relations page. Connect Biopharma is focused on developing therapies for chronic inflammatory diseases, with lead candidates including CBP-201 for atopic dermatitis and asthma, and CBP-307 for ulcerative colitis and Crohn’s disease.

SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the SVB Leerink 11^th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 4:20 pm ET.

A webcast of this fireside chat will be available on the Company’s Investor Relations page accessible here: https://investors.connectbiopharm.com/. A replay will be available on the Company’s website following the event.

About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.

Our lead product candidate, CBP-201 — an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) — has been in clinical trials for the treatment of AD, asthma, and CRSwNP. Our second lead product candidate, CBP-307 — a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) — has been in clinical trials for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we have started the clinical development of an additional product candidate, CBP-174 — a peripherally acting antagonist of histamine receptor 3 — for the treatment of pruritus associated with AD.

With clinical development activities in the United States, China, Europe, and Australia, and operations in those geographies as well as Hong Kong, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com.

IR/PR Contacts: 
Lazar FINN Partners 
David Carey (IR) 
T: +1-(212) 867-1768
david.carey@finnpartners.com

Erich Sandoval (Media)
T: +1-(917)-497-2867
erich.sandoval@finnpartners.com

Corporate Contacts:
info@connectpharm.com

FAQ

When is Dr. Zheng Wei's fireside chat at the SVB Leerink Global Healthcare Conference?

Dr. Zheng Wei's fireside chat is scheduled for February 16, 2022, at 4:20 PM ET.

What is Connect Biopharma's stock symbol?

Connect Biopharma's stock symbol is CNTB.

Where can I watch the fireside chat for Connect Biopharma?

The fireside chat can be watched on Connect Biopharma's Investor Relations page.

What are the lead product candidates of Connect Biopharma?

Connect Biopharma's lead products include CBP-201 for atopic dermatitis and asthma, and CBP-307 for ulcerative colitis and Crohn’s disease.

What focus area is Connect Biopharma involved in?

Connect Biopharma is dedicated to improving therapies for chronic inflammatory diseases through T cell-driven research.